Goldman Sachs Group set a €84.00 ($97.67) target price on Gerresheimer (ETR:GXI) in a research report report published on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also commented on GXI. HSBC set a €85.00 ($98.84) price objective on Gerresheimer and gave the stock a buy rating in a research note on Monday, October 14th. Hauck & Aufhaeuser set a €50.00 ($58.14) target price on Gerresheimer and gave the company a sell rating in a research note on Tuesday, December 17th. Credit Suisse Group set a €87.00 ($101.16) target price on Gerresheimer and gave the company a buy rating in a research note on Tuesday, October 15th. Berenberg Bank set a €81.00 ($94.19) target price on Gerresheimer and gave the company a buy rating in a report on Wednesday, November 20th. Finally, Independent Research set a €69.00 ($80.23) price target on Gerresheimer and gave the stock a neutral rating in a research report on Tuesday, November 26th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of €73.07 ($84.96).

GXI stock opened at €71.95 ($83.66) on Monday. The company has a debt-to-equity ratio of 65.99, a current ratio of 0.81 and a quick ratio of 0.54. Gerresheimer has a 52-week low of €56.50 ($65.70) and a 52-week high of €74.80 ($86.98). The company has a 50-day moving average of €69.09 and a two-hundred day moving average of €68.37. The stock has a market capitalization of $2.26 billion and a price-to-earnings ratio of 10.91.

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Further Reading: Correction

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.